Cardiac Prosthetic Devices Market

Cardiac Prosthetic Devices Market, By Product Type (Heart Valves (Mechanical Heart Valves, Tissue Heart Valves(Tissue Heart Valves and Stentless Tissue Valves) and Transcatheter Heart Valves), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others (Academic & Research Institutes and Others)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Cardiac prosthetic devices include mechanical and tissue prosthetic heart valves, annuloplasty rings, pacemaker and defibrillator leads, tissue patches, artificial hearts, and ventricular assist devices. These are used to replace the heart's native valves that have been harmed or become ill. Over the forecast period, rising levels of hypertension are anticipated to fuel market expansion for cardiac prosthetic devices worldwide. The market is also expected to rise as a result of increased research and product introductions.

Market Dynamics

The key market players are focused on adopting various growth strategies such as product launches, partnerships, and others to strengthen their product portfolio and geographical presence in the market, which in turn is expected to drive the growth of the global cardiac prosthetics devices market over the forecast period. For instance, on June 8, 2023, Abbott, a medical device company, announced result data for MitraClip, which is a transcatheter edge-to-edge repair (TEER) device, and TriClip, a first-of-its-kind minimally invasive tricuspid heart valve repair device. The data reinforce the capabilities of the company's structural heart solutions for both mitral and tricuspid regurgitation (MR and TR) across a broad range of patient groups battling leaky heart valves.

Similarly, in October 2022, Ceryx Medical, a medical device company, in partnership with Osypka Medical, a medical device company, announced the development of a heart-pacing device for patients with heart failure and other cardiac conditions

Furthermore, in February 2022, Abbott, a medical device company, announced the launch of patient implants of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i pivotal clinical study. The implant of Abbott's investigational Aveir dual-chamber leadless pacemaker represents technological leadless pacing technology.

Key features of the study:

• This report provides an in-depth analysis of the global cardiac prosthetics devices market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cardiac prosthetics devices market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Abbott, Artivion, Inc., Medtronic, Boston Scientific Corporation, Edwards Lifesciences Corporation., Siemens Healthcare Private Limited, LivaNova PLC (sorin group), Asahi Kasei Corporation., OSYPKA MEDICAL, Lepu Medical, MicroPort Scientific Corporation., Vitatron, Koninklijke Philips N.V., Progetti srl and Shree Pacetronix Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global Cardiac Prosthetics Devices Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cardiac prosthetics devices market.

Detailed Segmentation:

• Global Cardiac Prosthetic Devices Market, By Product Type:
• Heart Valves
• Mechanical Heart Valves
• Tissue Heart Valves
• Stented tissue valve
• Stentless tissue valve
• Transcatheter Heart Valves
• Pacemaker
• Implantable pacemakers
• Single-Chamber Battery Pacemaker
• Dual-Chamber Battery Pacemaker
• Triple-Chamber Battery Pacemaker
• External Pacemaker
• Global Cardiac Prosthetic Devices Market, By End user:
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others (Academic & Research Institutes and Others)
• Global Cardiac Prosthetic Devices Market, By Region:
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Abbott.
• Artivion, Inc.
• Medtronic
• Boston Scientific Corporation
• Edwards Lifesciences Corporation.
• Siemens Healthcare Private Limited
• LivaNova PLC (Sorin Group)
• Asahi Kasei Corporation.
• OSYPKA MEDICAL
• Lepu Medical
• MicroPort Scientific Corporation.
• Vitatron
• Koninklijke Philips N.V.,
• Progetti srl
• Shree Pacetronix Ltd.